Quantum BioPharma's MS Imaging Study with MGH Hits Midpoint, Showing Promising Early Data
QNTM has more than doubled off its 52-week low of $2.07.
Summary
Quantum BioPharma announced a significant midpoint milestone in its collaborative imaging study with Massachusetts General Hospital, reporting encouraging preliminary data. This study is validating a novel PET imaging technique using the [¹⁸F]3F4AP tracer to assess demyelination in multiple sclerosis (MS) patients, which could significantly enhance the evaluation of therapies like Quantum's investigational candidate, Lucid-MS. The preliminary analyses indicate robust signals in acute MS lesions. This positive development follows the company's recent IND filing for Lucid-MS in March 2026 and its strengthened liquidity. The successful validation of this imaging approach could accelerate the development and de-risk future clinical trials for Lucid-MS, providing a more precise measure of treatment impact on myelin preservation and regeneration. Investors should watch for further updates on both the imaging study's full results and the progression of Lucid-MS into Phase 2 clinical trials.
At the time of this announcement, QNTM was trading at $6.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $39.7M. The 52-week trading range was $2.07 to $38.25. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.